kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human FcGR2A /CD32a (H167) Protein, His Tag (SPR & BLI & MALS verified), 1mg  

Recombinant Human FcGR2A /CD32a (H167) Protein, His Tag (SPR & BLI & MALS verified), 1mg

Recombinant Human FcGR2A / CD32a (H167) Protein, Ala 36 - Ile 218, produced in human 293 cells, His Tag (SPR & BLI & MALS verified)

Recombinant, human, protein CD32a,FCGR2A,CD32,FCG2 ,FCGR2A1,IGFR2

More details


Availability: within 7 days

2 200,00 €

Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily that function in the activation or inhibition of immune responses. Three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized. There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. The activating isoform, CD32A, is expressed on monocytes, neutrophils, platelets and dendritic cells. CD32A is expressed on many immune cell types (macrophage, neutrophil, eosinophils, platelets, dendritic cells and Langerhan cells), where inhibitory ITIM­bearing receptors may also be coexpressed and co­engaged by specific ligands. CD32A delivers an activating signal upon ligand binding, and results in the initiation of inflammatory responses including cytolysis, phagocytosis, degranulation and cytokine production. The responses can be modulated by signals from the coexpressed inhibitory receptors such as CD32B, and the strength of the signal is dependent on the ratio of expression of the activating and inhibitory receptors.

Recombinant Human CD32a (H167), His Tag (CD1-H5223) is expressed from human 293 cells (HEK293). It contains AA Ala 36 - Ile 218 (Accession # P12318-1).
Predicted N-terminus: Ala 36

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 21.5 kDa. The protein migrates as 29-32 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.

Please refer to product data sheet.


Use BIAFFINS FcyR BINDING ASSAYS for detailed kinetic analysis of your antibodies using SPR.

Figure: Real-time kinetic analysis of antibody binding to FcγRIIa using surface plasmon resonance.

Clinical and Translational Updates

(1) "Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton's Tyrosine Kinase"
Duan, Goldmann, Li et al
Int J Mol Sci (2021) 23 (1)
(2) "Role of Fcγ receptors in HER2-targeted breast cancer therapy"
Musolino, Gradishar, Rugo et al
J Immunother Cancer (2022) 10 (1)
(3) "Platelet FcγRIIA-induced serotonin release exacerbates the severity of transfusion-related acute lung injury in mice"
El Mdawar, Maître, Magnenat et al
Blood Adv (2021) 5 (23), 4817-4830
Showing 1-3 of 46 papers.

The following products could also be interesting for you: